Summary Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose multiagent chemotherapy. High dose cisplatin (200mg m2) combined with etoposide (500mg m2), HIPE, was alternated with ifosfamide (9 g m2), vincristine (1.5 mg m2), and adriamycin (60mg m-'), IVAd 
Summary Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose multiagent chemotherapy. High dose cisplatin (200mg m2) combined with etoposide (500mg m2), HIPE, was alternated with ifosfamide (9 g m2), vincristine (1.5 mg m2), and adriamycin (60mg m-'), IVAd. Disease status was re-evaluated 3 to 4 weeks after the fourth course and the response classified according to the International Neuroblastoma Response Criteria (INRC) . The overall response rate in evaluable patients was 55% and response rates by site were: bone marrow 67% (complete response 47%); bone scan 68%; primary tumour 61%, and urinary catecholamine metabolites (VMA/HVA) 95%. Serial 51Cr EDTA renal clearance studies showed a glomerular filtration rate (GFR) decline in 40% of patients but in only seven cases to below 50% of the pretreatment value. There was no instance of renal failure during induction, though two patients developed severe renal failure following 'megatherapy' given to consolidate remission. Serial audiometry showed a significant decline in hearing at frequencies above 2,000 Hz in 37% of children but at or below 2,000 Hz in only 17%. Neutropenia and thrombocytopenia were severe and intravenous antibiotics were required after 30% of courses. Each of two treatment-related deaths occurred during pancytopenia following courses of IVAd. Complete, or greater than 90%, removal of primary site tumour was possible in 70% of cases following this induction regimen and 75% of patients proceeded to elective megatherapy within a median time of 24 weeks after diagnosis. This short intensive induction programme is highly effective at achieving cytoreduction, enabling early surgery and early megatherapy procedures. It is, however, too early to draw firm conclusions about the impact of this approach to treatment on the cure rate.
The management of metastatic neuroblastoma in children over one year of age remains one of the most frustrating areas of paediatric oncology. Early chemotherapy regimens based on cyclophosphamide, adriamycin and vincristine achieved responses but very few long-term survivors. Progression-free survival beyond 3 years was around 10%. (Ninane et al., 1981; Finklestein et al., 1979; Nitschke et al., 1980) . The addition of other agents such as mustine and DTIC had little impact (Rosen et al., 1984) . The introduction of VM26 and cisplatin improved the initial remission rate (Hayes et al., 1981) . Regimens based on this combination are now widely used and with surgery to the primary site complete remission rates in the region of 60% are achieved. However, long-term survival still remains around 20% at best (Rosen et al., 1984; Shafford et al., 1984; Bernard et al., 1987; Kushner et al., 1987) . 'Megatherapy' procedures, using agents such as high dose melphalan, total body irradiation, or other chemotherapy combinations with bone marrow rescue, prolong progression-free survival but have only had a marginal impact on the cure rate. To date, the most optimistic reports describe progression-free survival rates of around 30% at 3 years .
From evaluated in untreated patients with advanced neuroblastoma. The toxicity of these regimens was found to be acceptable and the response rates were 44% and 70%, respectively. In ENSG 3C these agents were combined with vincristine and adriamycin in a regimen designed to administer the maximum amount of drug tolerable as 3 to 4 weekly pulses over a short period. The aim was to determine if this approach would improve the complete response rate by comparison with lower dose regimens.
Patients and methods
Fifty-one unselected patients presenting sequentially between January 1986 and November 1987 to the participating centres and diagnosed to have Stage IV neuroblastoma, Evans and INSS classification (Brodeur et al., 1988) , were included in this study.
Age at presentation ranged from 15 months to 13 years 5 months (median 38 months) and there were 31 boys. Staging investigations are listed in Table I and included bone marrow aspirates and trephines, radioisotope bone scan, abdominal ultrasound and/or CT scan, and measurement of urinary catecholamine metabolites, VMA and HVA. Sites of initial disease are given in Table II . The chemotherapy regimens HIPE and IVAd with fluid and electrolyte supplementation are shown in Table III . A total of four courses was given with an interval of 21 to 28 days, or as soon as the blood count had recovered.
Disease status was fully re-assessed 3 to 4 weeks after the fourth course of therapy using the same investigations as at diagnosis. Marrow re-evaluation involved at least four sites, including a minimum of two trephine biopsies. MIBG scans performed in nine patients before and after therapy are not included in the formal definition of response according to current INSS guidelines. Serial serum electrolytes, including magnesium, calcium and phosphate, liver enzymes, and 51Cr EDTA GFR were monitored throughout therapy. Audiography was done in 30 patients. In 26 children old enough to co-operate, formal audiograms were obtained, whilst in four younger children, hearing was evaluated by the Kendall toy test. To standardize audiographic evaluation, the scoring system devised by Brock et al. (1988) was used (Table  IV) . Myelosuppression, transfusion requirements, treatment for infection and weight loss were also documented. Table I shows the overall schema of the study. Response was classified (Table V) according to the International Neuroblastoma Staging System (Brodeur et al., 1988) .
Results
The median duration of chemotherapy, start of course 1 to start of course 4, was 78 days (range 68-88 days). The median interval between courses of chemotherapy was 26 days following HIPE (range 21-28 days) and 24 days after IVAd (range 17-60 days). (Table V) . They fall between a partial response (PR), which is not possible as two or more marrows are positive, and a mixed response (MR), which is also (Table IV) .
Most patients proceeded to megatherapy after surgical resection of primary tumour. In most cases no further chemotherapy was given in the interval, although some poor responders received further IVAd after the formal re-evaluation at week 12.
Megatherapy regimens varied widely between centres with combinations of melphalan, carmustine, teniposide, vincristine, cisplatin and total body irradiation (TBI). In some patients double procedures were performed Hartmann et al., 1987) . Some units purged marrow with monoclonal antibody or Asta Z. It is therefore impossible to draw conclusions about the effect of high dose induction chemotherapy on subsequent bone marrow graft function or general toxicity.
There were, however, four treatment-related deaths follow- Complete response rates in marrow with other recently reported platinum-containing regimens given over several months are somewhat higher; 70% with PE-CADO or N4SE (Kushner et al., 1987) and 66% with OPEC (Shafford et al., 1984) for Stage IV patients aged over one year at diagnosis. Sufficient response data are published for PE-CADO (Hartmann et al., 1988) .
The dose of cisplatin used in this study (200 mg m-2 divided over five days) appears to be the maximum tolerable. Attempts to escalate beyond this level have been associated with unacceptable intestinal toxicity (Clerico et al., 1987) . The renal and auditory toxicity is comparable to that of the same total dose of platinum given over 8 to 10 courses (Shafford et al., 1984) . Although a third course is within the limits of renal tolerance, high tone hearing loss extends towards the normal hearing range. It is possible that, using a continuous infusion regimen, the number of courses tolerated can be increased (Castello et al., in press) . Etoposide has been shown to be more active when given in a divided dose regimen in small cell lung cancer (Cavalli et al., 1978) and although doses up to 2.4 g m2 as single agent have been used in leukaemia (Bostrom et al., 1987) , in combination with high dose platinum the dose of 500 mg m-2 approaches the limits of acceptable myelotoxicity. The dose of ifosfamide is near the maximum used in phase II paediatric studies (Pinkerton et al., 1985; de Kraker et al., 1984) and has been found to be active in neuroblastoma and paediatric sarcomas either alone or in combination with agents such as etoposide or cisplatin (Pratt et al., 1986) . At high doses central nervous system and renal tubular toxicities are limiting factors. With a cumulative dose of only 120 mgm2 adriamycin-related cardiotoxicity should not be a problem so it is worrying that two patients showed evidence of cardiac dysfunction. The possibility of ifosfamide contributing to anthracycline toxicity has recently been raised (Oberlin et al., 1988) .
The use of supposedly non-cross resistant regimens in an alternating sequence has gained popularity in cancer chemotherapy. There is some evidence that high dose platinum/ etoposide is effective in patients who have failed to respond to regimens containing cyclophosphamide , but any advantage due to this method of scheduling in neuroblastoma remains theoretical. Whether ifosfamide is superior to cyclophosphamide is also debatable (Oberlin et al., 1988; Jurgens et al., 1988) and although improved response rates in rhabdomyosarcoma and Ewing's sarcoma have been claimed (Treuner et al., 1987; de Kraker et al., 1987) , there is yet no randomized study in neuroblastoma or any other paediatric tumour. The beneficial effect of dose escalation of cyclophosphamide in neuroblastoma has been clearly shown (Kushner et al., 1987) and the lower myelotoxicity of ifosfamide enables a higher dose to be given. The response rate to ifosfamide alone in relapsed neuroblastoma was disappointing (de Karker et al., 1987) , but direct comparison with single agent cyclophosphamide is not possible because such studies were done in the 1960s when virtually no attempt at objective response measurement was made. Alternative treatment strategies to improve response rates are under investigation, for example, a United Kingdom Children's Cancer Study Group (UKCCSG) phase II study of MIBG linked '1'I therapy is in progress.
In conclusion, the HIPE/IVAd regimen is a short, effective induction regimen enabling early consolidation with megatherapy procedures. The overall complete response rate was not better than that achieved with similar total drug doses given over a more prolonged period but the impact of achieving a response earlier awaits further follow up. Further increase in dose intensity with administration of cisplatin at day 10 between courses of combination chemotherapy is also being evaluated (Pearson et al., 1988) and such a 'rapid delivery high dose intensity' schedule will be the subject of the next ENSG randomized trial.
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